Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 2/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19628140 | 0.88 | MEN1 (0.38) | ALOX5TNKSTNKS2GPR84PTPN1 | |
| SCHEMBL14882843 | 0.86 | ALOX5 (0.39) | ALOX5APPTNKSTNKS2GPR84 | |
| SCHEMBL19628174 | 0.86 | GPR84 (0.32) | GPR84 | |
| SCHEMBL14725663 | 0.85 | ALOX5 (0.39) | ALOX5APPTNKSTNKS2GPR84 | |
| SCHEMBL24888760 | 0.85 | GPR84 (0.36) | ALOX5APPTNKSTNKS2GPR84 | |
| SCHEMBL19628185 | 0.85 | ALOX5 (0.41) | ALOX5TNKSTNKS2F9ALDH1A1 | |
| SCHEMBL25881157 | 0.85 | GPR84 (0.36) | ALOX5APPTNKSTNKS2GPR84 | |
| SCHEMBL14961985 | 0.84 | ALDH1A1 (0.40) | APPGPR84KDM4EMEN1ALDH1A1 | |
| SCHEMBL19628178 | 0.84 | MEN1 (0.35) | ALOX5TNKSTNKS2GPR84PTPN1 | |
| SCHEMBL15197364 | 0.83 | ALDH1A1 (0.39) | APPGPR84KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10439144-B2 | Organic compound for electronic device comprising fused-core structure, organic optoelectronic device comprising same, and display device | UNIVERSITY-INDUSTRY COOPERATEON GROUP OF KYUNG HEE UNIVERSITY (KR) | 2019-10-08 | — | — | US | disclosed |
| US-20170338416-A1 | ORGANIC COMPOUND FOR ELECTRONIC DEVICE COMPRISING FUSED-CORE STRUCTURE, ORGANIC OPTOELECTRONIC DEVICE COMPRISING SAME, AND DISPLAY DEVICE | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170338416-A1 | ORGANIC COMPOUND FOR ELECTRONIC DEVICE COMPRISING FUSED-CORE STRUCTURE, ORGANIC OPTOELECTRONIC DEVICE COMPRISING SAME, AND DISPLAY DEVICE | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10439144-B2 | Organic compound for electronic device comprising fused-core structure, organic optoelectronic device comprising same, and display device | OR10J3, OCIAD2, OCIAD1 | ALOX5 1129/4885APP 464/4885TNKS 4514/4885 |
| US-20170338416-A1 | ORGANIC COMPOUND FOR ELECTRONIC DEVICE COMPRISING FUSED-CORE STRUCTURE, ORGANIC OPTOELECTRONIC DEVICE COMPRISING SAME, AND DISPLAY DEVICE | OR10J3, OCIAD2, OCIAD1 | ALOX5 1129/4885APP 464/4885TNKS 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.